Furthermore, the discovery of the BRAF mutation in melanoma led to the approval of the BRAF inhibitors vemurafenib (VEM) in 2011 and dabrafenib (DAB) in 2013, after which the MEK inhibitors cobimetinib (COB) and trametinib (TRAM) were approved for combination therapy with BRAF inhibitors [7]. The gene discussed is BRAF; the disease is melanoma.